[1]	中华医学会罕见病分会, 北京医学会罕见病分会. Duchenne型肌营养不良多学科管理指南[J]. 中华内科杂志, 2025, 64(9): 812-824. DOI: 10.3760/cma.j.cn112138-20250412-00210 . Cited in this article [4]

[2]

Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management[J]. Lancet Neurol, 2018, 17(4): 347-361. PMCID: PMC5889091. DOI: 10.1016/S1474-4422(18)30025-5 . https://www.ncbi.nlm.nih.gov/pubmed/29395990 Cited in this article [2]

[3]	Zhao L, Shi Y, Hu C, et al. Comprehensive analysis of 2 097 patients with dystrophinopathy based on a database from 2011 to 2021[J]. Orphanet J Rare Dis, 2024, 19(1): 311. PMCID: PMC11344408. DOI: 10.1186/s13023-024-03217-7 . https://www.ncbi.nlm.nih.gov/pubmed/39182149 Cited in this article [1]

[4]

Pioner JM, Guan X, Klaiman JM, et al. Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes derived from human-induced pluripotent stem cells[J]. Cardiovasc Res, 2020, 116(2): 368-382. PMCID: PMC8053310. DOI: 10.1093/cvr/cvz109 . https://www.ncbi.nlm.nih.gov/pubmed/31049579 Cited in this article [1]

[5]

Yamamoto T, Awano H, Zhang Z, et al. Cardiac dysfunction in Duchenne muscular dystrophy is less frequent in patients with mutations in the dystrophin Dp116 coding region than in other regions[J]. Circ Genom Precis Med, 2018, 11(1): e001782. PMCID: PMC6319568. DOI: 10.1161/CIRCGEN.117.001782 . https://www.ncbi.nlm.nih.gov/pubmed/29874176 Cited in this article [1]

[6]	Gorgoglione D, Sabbatini D, Riguzzi P, et al. Natural history of Becker muscular dystrophy: DMD gene mutations predict clinical severity[J]. Brain, 2025, 148(5): 1695-1706. DOI: 10.1093/brain/awae358 . https://www.ncbi.nlm.nih.gov/pubmed/39499670 Cited in this article [1]

[7]	Cirino RHD, Scola RH, Ducci RD, et al. Predictors of early left ventricular systolic dysfunction in Duchenne muscular dystrophy patients[J]. Muscle Nerve, 2018, 58(1): 84-89. DOI: 10.1002/mus.26102 . https://www.ncbi.nlm.nih.gov/pubmed/29443387 Cited in this article [1]

[8]

Amoasii L, Long C, Li H, et al. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy[J]. Sci Transl Med, 2017, 9(418): eaan8081. PMCID: PMC5749406. DOI: 10.1126/scitranslmed.aan8081 . https://www.ncbi.nlm.nih.gov/pubmed/29187645 Cited in this article [1]

[9]	Chang AC, Ong SG, LaGory EL, et al. Telomere shortening and metabolic compromise underlie dystrophic cardiomyopathy[J]. Proc Natl Acad Sci U S A, 2016, 113(46): 13120-13125. PMCID: PMC5135315 . DOI: 10.1073/pnas.1615340113 . https://www.ncbi.nlm.nih.gov/pubmed/27799523 Cited in this article [1]

[10]

Haffner V, Nourian Z, Boerman EM, et al. Calcium handling dysfunction and cardiac damage following acute ventricular preload challenge in the dystrophin-deficient mouse heart[J]. Am J Physiol Heart Circ Physiol, 2023, 325(5): H1168-H1177. PMCID: PMC10907071. DOI: 10.1152/ajpheart.00265.2023 . https://www.ncbi.nlm.nih.gov/pubmed/37737731 Cited in this article [1]

[11]	Stevens JA, Dobratz TC, Fischer KD, et al. Mechanisms of reduced myocardial energetics of the dystrophic heart[J]. Am J Physiol Heart Circ Physiol, 2024, 326(2): H396-H407. PMCID: PMC11219055. DOI: 10.1152/ajpheart.00636.2023 . https://www.ncbi.nlm.nih.gov/pubmed/38099842 Cited in this article [1]

[12]	Mourkioti F, Kustan J, Kraft P, et al. Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy[J]. Nat Cell Biol, 2013, 15(8): 895-904. PMCID: PMC3774175. DOI: 10.1038/ncb2790 . https://www.ncbi.nlm.nih.gov/pubmed/23831727 Cited in this article [1]

[13]

Duelen R, Costamagna D, Gilbert G, et al. Human iPSC model reveals a central role for NOX4 and oxidative stress in Duchenne cardiomyopathy[J]. Stem Cell Reports, 2022, 17(2): 352-368. PMCID: PMC8828550. DOI: 10.1016/j.stemcr.2021.12.019 . https://www.ncbi.nlm.nih.gov/pubmed/35090586 Cited in this article [1]

[14]

Zhou D, Li Y, Hu Q, et al. Early identification of persistent progressive myocardial injury in Duchenne muscular dystrophy: a prospective, single-center cohort study[J]. Sci Rep, 2026, 16(1): 19763. PMCID: PMC13316041. DOI: 10.1038/s41598-026-46507-9 . https://www.ncbi.nlm.nih.gov/pubmed/42031836 Cited in this article [1]

[15]	Yamaguchi H, Awano H, Yamamoto T, et al. Serum cardiac troponin I is a candidate biomarker for cardiomyopathy in Duchenne and Becker muscular dystrophies[J]. Muscle Nerve, 2022, 65(5): 521-530. DOI: 10.1002/mus.27522 . https://www.ncbi.nlm.nih.gov/pubmed/35174514 Cited in this article [1]

[16]

Awano H, Nambu Y, Osawa K, et al. Urinary titin reflects the severity of walking ability, muscle strength, and muscle and cardiac damage in patients with Becker muscular dystrophy[J]. Clin Chim Acta, 2025, 566: 120053. DOI: 10.1016/j.cca.2024.120053 . https://www.ncbi.nlm.nih.gov/pubmed/39561886 Cited in this article [1]

[17]

Becker S, Florian A, Patrascu A, et al. Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach[J]. J Cardiovasc Magn Reson, 2016, 18(1): 25. PMCID: PMC4858897. DOI: 10.1186/s12968-016-0244-3 . https://www.ncbi.nlm.nih.gov/pubmed/27150296 Cited in this article [1]

[18]	张琳玲, 王川, 谢佩环, 等. 杜氏肌营养不良男性患儿486份心电图特征病例系列报告[J]. 中国循证儿科杂志, 2023, 18(4): 255-260. DOI: 10.3969/j.issn.1673-5501.2023.04.002 . Cited in this article [1]

[19]	Tang L, Shao S, Wang C. Electrocardiographic features of children with Duchenne muscular dystrophy[J]. Orphanet J Rare Dis, 2022, 17(1): 320. PMCID: PMC9392256. DOI: 10.1186/s13023-022-02473-9 . https://www.ncbi.nlm.nih.gov/pubmed/35987773 Cited in this article [1]

[20]

Yamamoto T, Nambu Y, Bo R, et al. Electrocardiographic R wave amplitude in V6 lead as a predictive marker of cardiac dysfunction in Duchenne muscular dystrophy[J]. J Cardiol, 2023, 82(5): 363-370. DOI: 10.1016/j.jjcc.2023.07.003 . https://www.ncbi.nlm.nih.gov/pubmed/37481234 Cited in this article [1]

[21]

Yamamoto T, Ogawa S, Ide Y, et al. Fragmented QRS in lateral leads on electrocardiography is associated with cardiac dysfunction and left ventricular dilation in Duchenne muscular dystrophy[J]. Biomedicines, 2025, 13(4): 804. PMCID: PMC12024901. DOI: 10.3390/biomedicines13040804 . https://www.ncbi.nlm.nih.gov/pubmed/40299328 Cited in this article [1]

[22]

RMFLD Silva, Monteze NM, Giannetti JG, et al. Electrocardiographic and autonomic nervous system changes after changes in the posture of children and adolescents with Duchenne muscular dystrophy[J]. Arq Bras Cardiol, 2024, 121(2): e20230483. PMCID: PMC12092046. DOI: 10.36660/abc.20230483 . https://www.ncbi.nlm.nih.gov/pubmed/38597534 Cited in this article [1]

[23]

Awano H, Nambu Y, Itoh C, et al. Longitudinal data of serum creatine kinase levels and motor, pulmonary, and cardiac functions in 337 patients with Duchenne muscular dystrophy[J]. Muscle Nerve, 2024, 69(5): 604-612. DOI: 10.1002/mus.28073 . https://www.ncbi.nlm.nih.gov/pubmed/38511270 Cited in this article [1]

[24]	Buddhe S, Lewin M, Olson A, et al. Comparison of left ventricular function assessment between echocardiography and MRI in Duchenne muscular dystrophy[J]. Pediatr Radiol, 2016, 46(10): 1399-1408. DOI: 10.1007/s00247-016-3622-y . https://www.ncbi.nlm.nih.gov/pubmed/27173979 Cited in this article [1]

[25]

Lechner A, Herzig JJ, Kientsch JG, et al. Cardiomyopathy as cause of death in Duchenne muscular dystrophy: a longitudinal observational study[J]. ERJ Open Res, 2023, 9(5): 00176-2023. PMCID: PMC10505954. DOI: 10.1183/23120541.00176-2023 . https://www.ncbi.nlm.nih.gov/pubmed/37727676 Cited in this article [1]

[26]	姚凤娟, 郑菊, 陆堃, 等. 血流多普勒Tei指数对进行性肌营养不良患者左心功能的探讨[J]. 影像诊断与介入放射学, 2007, 16(5): 203-205. DOI: 10.3969/j.issn.1005-8001.2007.05.004 . Cited in this article [1]

[27]

Amedro P, Vincenti M, De La Villeon G, et al. Speckle-tracking echocardiography in children with Duchenne muscular dystrophy: a prospective multicenter controlled cross-sectional study[J]. J Am Soc Echocardiogr, 2019, 32(3): 412-422. DOI: 10.1016/j.echo.2018.10.017 . https://www.ncbi.nlm.nih.gov/pubmed/30679141 Cited in this article [1]

[28]

Lanot N, Vincenti M, Abassi H, et al. Assessment of left ventricular dyssynchrony by speckle tracking echocardiography in children with Duchenne muscular dystrophy[J]. Int J Cardiovasc Imaging, 2022, 38(1): 79-89. DOI: 10.1007/s10554-021-02369-y . https://www.ncbi.nlm.nih.gov/pubmed/34905152 Cited in this article [1]

[29]

Yu HK, Xia B, Liu X, et al. Initial application of three-dimensional speckle-tracking echocardiography to detect subclinical left ventricular dysfunction and stratify cardiomyopathy associated with Duchenne muscular dystrophy in children[J]. Int J Cardiovasc Imaging, 2019, 35(1): 67-76. DOI: 10.1007/s10554-018-1436-8 . https://www.ncbi.nlm.nih.gov/pubmed/30105418 Cited in this article [1]

[30]

Hor KN, Taylor MD, Al-Khalidi HR, et al. Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function[J]. J Cardiovasc Magn Reson, 2013, 15(1): 107. PMCID: PMC3896985. DOI: 10.1186/1532-429X-15-107 . https://www.ncbi.nlm.nih.gov/pubmed/24359596 Cited in this article [1]

[31]

Zhou Z, Xu R, Cai X, et al. Association between myocardial oxygenation and fibrosis in Duchenne muscular dystrophy: analysis by rest oxygenation-sensitive magnetic resonance imaging[J]. J Magn Reson Imaging, 2024, 60(5): 1989-1999. DOI: 10.1002/jmri.29273 . https://www.ncbi.nlm.nih.gov/pubmed/38328865 Cited in this article [1]

[32]

Batra A, Barnard AM, Lott DJ, et al. Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging[J]. BMC Cardiovasc Disord, 2022, 22(1): 260. PMCID: PMC9185987. DOI: 10.1186/s12872-022-02688-5 . https://www.ncbi.nlm.nih.gov/pubmed/35681116 Cited in this article [1]

[33]

Schiava M, Lofra RM, Bourke JP, et al. Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids[J]. Eur J Neurol, 2024, 31(6): e16267. PMCID: PMC11236054. DOI: 10.1111/ene.16267 . https://www.ncbi.nlm.nih.gov/pubmed/38556893 Cited in this article [1]

[34]

Wittlieb-Weber CA, Knecht KR, Villa CR, et al. Risk factors for cardiac and non-cardiac causes of death in males with Duchenne muscular dystrophy[J]. Pediatr Cardiol, 2020, 41(4): 764-771. PMCID: PMC7328368. DOI: 10.1007/s00246-020-02309-y . https://www.ncbi.nlm.nih.gov/pubmed/32016582 Cited in this article [1]

[35]	McCormack NM, Nguyen NY, Tully CB, et al. Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice[J]. iScience, 2023, 26(7): 107161. PMCID: PMC10391915. DOI: 10.1016/j.isci.2023.107161 . https://www.ncbi.nlm.nih.gov/pubmed/37534133 Cited in this article [1]

[36]

Dang UJ, Damsker JM, Guglieri M, et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial[J]. Neurology, 2024, 102(5): e208112. PMCID: PMC11067696. DOI: 10.1212/WNL.0000000000208112 . https://www.ncbi.nlm.nih.gov/pubmed/38335499 Cited in this article [1]

[37]

Mah JK, Gonorazky HD, Nigro E, et al. Vamorolone safety, pharmacokinetics, and exploratory efficacy in Duchenne muscular dystrophy: a phase II, nonrandomized, multiple-dose study in 2-<4-year-old boys[J]. Neurology, 2026, 106(11): e218066. PMCID: PMC13225237. DOI: 10.1212/WNL.0000000000218066 . https://www.ncbi.nlm.nih.gov/pubmed/42139656

[38]

Lochmüller H, Gonorazky H, Nigro E, et al. Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with Duchenne muscular dystrophy[J]. J Neurol, 2026, 273(3): 177. PMCID: PMC12957623. DOI: 10.1007/s00415-026-13711-6 . https://www.ncbi.nlm.nih.gov/pubmed/41774261 Cited in this article [1]

[39]	Ibrahim MS, Abdelwahab OA, Elawfi B, et al. Meta-analysis of the efficacy and safety of vamorolone in Duchenne muscular dystrophy[J]. Neurol Sci, 2025, 46(5): 2249-2262. PMCID: PMC12003609. DOI: 10.1007/s10072-024-07939-1 . https://www.ncbi.nlm.nih.gov/pubmed/39715964 Cited in this article [1]

[40]

Porcher R, Desguerre I, Amthor H, et al. Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy: analysis of registry data[J]. Eur Heart J, 2021, 42(20): 1976-1984. DOI: 10.1093/eurheartj/ehab054 . https://www.ncbi.nlm.nih.gov/pubmed/33748842 Cited in this article [1]

[41]

Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2015, 14(2): 153-161. PMCID: PMC4361281. DOI: 10.1016/S1474-4422(14)70318-7 . https://www.ncbi.nlm.nih.gov/pubmed/25554404 Cited in this article [1]

[42]

Raman SV, Hor KN, Mazur W, et al. Stabilization of early Duchenne cardiomyopathy with aldosterone inhibition: results of the multicenter AIDMD trial[J]. J Am Heart Assoc, 2019, 8(19): e013501. PMCID: PMC6806050. DOI: 10.1161/JAHA.119.013501 . https://www.ncbi.nlm.nih.gov/pubmed/31549577 Cited in this article [1]

[43]

Arcudi A, Di Francesco M, Rodolico D, et al. Angiotensin receptor-neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: a primetime[J]. ESC Heart Fail, 2022, 9(5): 3639-3642. PMCID: PMC9715800. DOI: 10.1002/ehf2.13963 . https://www.ncbi.nlm.nih.gov/pubmed/35712811 Cited in this article [1]

[44]	Tochinai R, Kimura K, Saika T, et al. Ivabradine ameliorates cardiomyopathy progression in a Duchenne muscular dystrophy model rat[J]. Exp Anim, 2024, 73(2): 145-153. PMCID: PMC11091361. DOI: 10.1538/expanim.23-0087 . https://www.ncbi.nlm.nih.gov/pubmed/37914289 Cited in this article [1]

[45]

Bourke JP, Bryant A, Landon G, et al. Preventing cardiomyopathy in Duchenne muscular dystrophy: long-term follow-up of patients in the randomised, placebo-controlled drug-trial of perindopril and bisoprolol[J]. Eur J Neurol, 2025, 32(3): e70097. PMCID: PMC11933849. DOI: 10.1111/ene.70097 . https://www.ncbi.nlm.nih.gov/pubmed/40130400 Cited in this article [1]

[46]

Kelley EF, Cross TJ, McDonald CM, et al. Influence of β1 adrenergic receptor genotype on longitudinal measures of left ventricular ejection fraction and responsiveness to β-blocker therapy in patients with Duchenne muscular dystrophy[J]. Clin Med Insights Cardiol, 2022, 16: 11795468221116838. PMCID: PMC9421016. DOI: 10.1177/11795468221116838 . https://www.ncbi.nlm.nih.gov/pubmed/36046180 Cited in this article [1]

[47]	Rosenthal DN, Amodeo A, Butterfield RJ, et al. Heart transplantation and ventricular assist device in Duchenne muscular dystrophy: a new era[J]. Pediatr Transplant, 2026, 30(1): e70253. DOI: 10.1111/petr.70253 . https://www.ncbi.nlm.nih.gov/pubmed/41424087 Cited in this article [1]

[48]

Iff J, Desguerre I, Liu Y, et al. Association between exon-skipping therapy with eteplirsen and cardiac outcomes in Duchenne muscular dystrophy[J]. J Neuromuscul Dis, 2026, 13(2): 179-189. PMCID: PMC13141851. DOI: 10.1177/22143602251366721 . https://www.ncbi.nlm.nih.gov/pubmed/40831143 Cited in this article [1]

[49]

Keselman DJ, Small JC, Seneviratne T, et al. Real-world outcomes of delandistrogene moxeparvovec gene therapy: motor outcomes and emerging safety concerns[J]. Mol Ther, 2026, 34(1): 123-130. PMCID: PMC12925777. DOI: 10.1016/j.ymthe.2025.10.007 . https://www.ncbi.nlm.nih.gov/pubmed/41047627 Cited in this article [1]

[50]

Duan D, Herzog RW. Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: underlying mechanisms and mitigating strategies[J]. Mol Ther, 2026, 34(4): 1893-1908. PMCID: PMC12882805. DOI: 10.1016/j.ymthe.2025.12.067 . https://www.ncbi.nlm.nih.gov/pubmed/41502088 Cited in this article [3]

[51]

Sherlock SP, Levy DI, McIntosh A, et al. Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: initial observations from a phase 1b trial[J]. Mol Ther, 2025, 33(9): 4216-4225. PMCID: PMC12432883. DOI: 10.1016/j.ymthe.2025.06.031 . https://www.ncbi.nlm.nih.gov/pubmed/40583273 Cited in this article [1]

[52]

Byrne BJ, Butterfield RJ, Shieh PB, et al. Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy[J]. Mol Ther, 2025, 33(9): 4226-4238. PMCID: PMC12432875. DOI: 10.1016/j.ymthe.2025.06.032 . https://www.ncbi.nlm.nih.gov/pubmed/40583275 Cited in this article [1]

[53]

Muntoni F, Nascimento A, Shin J, et al. Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study[J]. Lancet Neurol, 2026, 25(3): 245-255. DOI: 10.1016/S1474-4422(26)00036-0 . https://www.ncbi.nlm.nih.gov/pubmed/41722591 Cited in this article [1]

[54]

McDonald CM, Marbán E, Hendrix S, et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2022, 399(10329): 1049-1058. DOI: 10.1016/S0140-6736(22)00012-5 . https://www.ncbi.nlm.nih.gov/pubmed/35279258 Cited in this article [1]

[55]

Narra N, Richards AM, Earl CC, et al. Positive allosteric modulator of SERCA pump NDC-1171 attenuates cardiac functional decline in mouse model of Duchenne muscular dystrophy[J]. bioRxiv[Preprint]. (2026-03-09) [2026-06-03]. PMCID: PMC13061008. DOI: 10.64898/2026.03.05.709950 . https://www.ncbi.nlm.nih.gov/pubmed/41959099 Cited in this article [1]

[56]

Deng R, De Oliveira Silva T, Liu X, et al. Treatment with the Nox1/4 inhibitor Setanaxib ameliorates cardiac function in mouse models of Duchenne muscular dystrophy[J]. Mol Ther, 2026, Epub ahead of print. PMCID: PMC13453391. DOI: 10.1016/j.ymthe.2026.06.033 . https://www.ncbi.nlm.nih.gov/pubmed/42363603 Cited in this article [1]